Search

Your search keyword '"Bakker, S. D."' showing total 14 results
Start Over Author "Bakker, S. D."
14 results on '"Bakker, S. D."'

1. Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature

Author

Opdam, M., van der Noort, V., Kleijn, M., Glas, A., Mandjes, I., Kleiterp, S., Hilbers, F. S., Kruger, D. T., Bins, A. D., de Jong, P. C., Schiphorst, P. P. J. B. M., van Dalen, T., Flameling, B., Rietbroek, R. C., Beeker, A., van den Heiligenberg, S. M., Bakker, S. D., Wymenga, A. N. M., Oving, I. M., Bijlsma, R. M., van Diest, P. J., Vermorken, J. B., van Tinteren, H., and Linn, S. C.

Published
2022
Full Text
View/download PDF

4. Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer

Author

de Boo, L W, Jóźwiak, K; https://orcid.org/0000-0002-9614-6586, Ter Hoeve, N D, van Diest, P J; https://orcid.org/0000-0003-0658-2745, Opdam, M; https://orcid.org/0000-0001-5832-6386, Wang, Y; https://orcid.org/0000-0002-1482-7039, Schmidt, M K; https://orcid.org/0000-0002-2228-429X, de Jong, V, Kleiterp, S, Cornelissen, S, Baars, D, Koornstra, R H T, Kerver, E D; https://orcid.org/0009-0004-6456-4857, van Dalen, T, Bins, A D, Beeker, A; https://orcid.org/0000-0003-4133-769X, van den Heiligenberg, S M, de Jong, P C, Bakker, S D; https://orcid.org/0000-0003-3936-4648, Rietbroek, R C, Konings, I R, Blankenburgh, R, Bijlsma, R M; https://orcid.org/0000-0003-0980-6652, Imholz, A L T, Stathonikos, N, Vreuls, W; https://orcid.org/0000-0001-6661-6017, Sanders, J, Rosenberg, E H; https://orcid.org/0000-0002-3859-6941, Koop, E A, Varga, Z; https://orcid.org/0000-0002-2855-983X, et al, de Boo, L W, Jóźwiak, K; https://orcid.org/0000-0002-9614-6586, Ter Hoeve, N D, van Diest, P J; https://orcid.org/0000-0003-0658-2745, Opdam, M; https://orcid.org/0000-0001-5832-6386, Wang, Y; https://orcid.org/0000-0002-1482-7039, Schmidt, M K; https://orcid.org/0000-0002-2228-429X, de Jong, V, Kleiterp, S, Cornelissen, S, Baars, D, Koornstra, R H T, Kerver, E D; https://orcid.org/0009-0004-6456-4857, van Dalen, T, Bins, A D, Beeker, A; https://orcid.org/0000-0003-4133-769X, van den Heiligenberg, S M, de Jong, P C, Bakker, S D; https://orcid.org/0000-0003-3936-4648, Rietbroek, R C, Konings, I R, Blankenburgh, R, Bijlsma, R M; https://orcid.org/0000-0003-0980-6652, Imholz, A L T, Stathonikos, N, Vreuls, W; https://orcid.org/0000-0001-6661-6017, Sanders, J, Rosenberg, E H; https://orcid.org/0000-0002-3859-6941, Koop, E A, Varga, Z; https://orcid.org/0000-0002-2855-983X, and et al

Published
2024

5. Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer

Author

Pathologie, Cancer, MMB opleiding Arts microbioloog, Neurogenetica, MS CGO, Public Health Practice, Affectieve & Psychotische Med., MS Medische Oncologie, Pathologie Support, Pathologie Pathologen staf, MS Reumatologie/Immunologie/Infectie, Speerpunt Cancer, KVO Docenten, de Boo, L W, Jóźwiak, K, Ter Hoeve, N D, van Diest, P J, Opdam, M, Wang, Y, Schmidt, M K, de Jong, V, Kleiterp, S, Cornelissen, S, Baars, D, Koornstra, R H T, Kerver, E D, van Dalen, T, Bins, A D, Beeker, A, van den Heiligenberg, S M, de Jong, P C, Bakker, S D, Rietbroek, R C, Konings, I R, Blankenburgh, R, Bijlsma, R M, Imholz, A L T, Stathonikos, N, Vreuls, W, Sanders, J, Rosenberg, E H, Koop, E A, Varga, Z, van Deurzen, C H M, Mooyaart, A L, Córdoba, A, Groen, E, Bart, J, Willems, S M, Zolota, V, Wesseling, J, Sapino, A, Chmielik, E, Ryska, A, Broeks, A, Voogd, A C, van der Wall, E, Siesling, S, Salgado, R, Dackus, G M H E, Hauptmann, M, Kok, M, Linn, S C, Pathologie, Cancer, MMB opleiding Arts microbioloog, Neurogenetica, MS CGO, Public Health Practice, Affectieve & Psychotische Med., MS Medische Oncologie, Pathologie Support, Pathologie Pathologen staf, MS Reumatologie/Immunologie/Infectie, Speerpunt Cancer, KVO Docenten, de Boo, L W, Jóźwiak, K, Ter Hoeve, N D, van Diest, P J, Opdam, M, Wang, Y, Schmidt, M K, de Jong, V, Kleiterp, S, Cornelissen, S, Baars, D, Koornstra, R H T, Kerver, E D, van Dalen, T, Bins, A D, Beeker, A, van den Heiligenberg, S M, de Jong, P C, Bakker, S D, Rietbroek, R C, Konings, I R, Blankenburgh, R, Bijlsma, R M, Imholz, A L T, Stathonikos, N, Vreuls, W, Sanders, J, Rosenberg, E H, Koop, E A, Varga, Z, van Deurzen, C H M, Mooyaart, A L, Córdoba, A, Groen, E, Bart, J, Willems, S M, Zolota, V, Wesseling, J, Sapino, A, Chmielik, E, Ryska, A, Broeks, A, Voogd, A C, van der Wall, E, Siesling, S, Salgado, R, Dackus, G M H E, Hauptmann, M, Kok, M, and Linn, S C

Published
2024

6. Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer

Author

de Boo, L. W., Jóźwiak, K., Ter Hoeve, N. D., van Diest, P. J., Opdam, M., Wang, Y., Schmidt, M. K., de Jong, V., Kleiterp, S., Cornelissen, S., Baars, D., Koornstra, R. H.T., Kerver, E. D., van Dalen, T., Bins, A. D., Beeker, A., van den Heiligenberg, S. M., de Jong, P. C., Bakker, S. D., Rietbroek, R. C., Konings, I. R., Blankenburgh, R., Bijlsma, R. M., Imholz, A. L.T., Stathonikos, N., Vreuls, W., Sanders, J., Rosenberg, E. H., Koop, E. A., Varga, Z., van Deurzen, C. H.M., Mooyaart, A. L., Córdoba, A., Groen, E., Bart, J., Willems, S. M., Zolota, V., Wesseling, J., Sapino, A., Chmielik, E., Ryska, A., Broeks, A., Voogd, A. C., van der Wall, E., Siesling, S., Salgado, R., Dackus, G. M.H.E., Hauptmann, M., Kok, M., Linn, S. C., de Boo, L. W., Jóźwiak, K., Ter Hoeve, N. D., van Diest, P. J., Opdam, M., Wang, Y., Schmidt, M. K., de Jong, V., Kleiterp, S., Cornelissen, S., Baars, D., Koornstra, R. H.T., Kerver, E. D., van Dalen, T., Bins, A. D., Beeker, A., van den Heiligenberg, S. M., de Jong, P. C., Bakker, S. D., Rietbroek, R. C., Konings, I. R., Blankenburgh, R., Bijlsma, R. M., Imholz, A. L.T., Stathonikos, N., Vreuls, W., Sanders, J., Rosenberg, E. H., Koop, E. A., Varga, Z., van Deurzen, C. H.M., Mooyaart, A. L., Córdoba, A., Groen, E., Bart, J., Willems, S. M., Zolota, V., Wesseling, J., Sapino, A., Chmielik, E., Ryska, A., Broeks, A., Voogd, A. C., van der Wall, E., Siesling, S., Salgado, R., Dackus, G. M.H.E., Hauptmann, M., Kok, M., and Linn, S. C.

Abstract

Background: In the absence of prognostic biomarkers, most patients with early-stage triple-negative breast cancer (eTNBC) are treated with combination chemotherapy. The identification of biomarkers to select patients for whom treatment de-escalation or escalation could be considered remains an unmet need. We evaluated the prognostic value of histopathologic traits in a unique cohort of young, (neo)adjuvant chemotherapy-naïve patients with early-stage (stage I or II), node-negative TNBC and long-term follow-up, in relation to stromal tumor-infiltrating lymphocytes (sTILs) for which the prognostic value was recently reported. Materials and methods: We studied all 485 patients with node-negative eTNBC from the population-based PARADIGM cohort which selected women aged <40 years diagnosed between 1989 and 2000. None of the patients had received (neo)adjuvant chemotherapy according to standard practice at the time. Associations between histopathologic traits and breast cancer-specific survival (BCSS) were analyzed with Cox proportional hazard models. Results: With a median follow-up of 20.0 years, an independent prognostic value for BCSS was observed for lymphovascular invasion (LVI) [adjusted (adj.) hazard ratio (HR) 2.35, 95% confidence interval (CI) 1.49-3.69], fibrotic focus (adj. HR 1.61, 95% CI 1.09-2.37) and sTILs (per 10% increment adj. HR 0.75, 95% CI 0.69-0.82). In the sTILs <30% subgroup, the presence of LVI resulted in a higher cumulative incidence of breast cancer death (at 20 years, 58%; 95% CI 41% to 72%) compared with when LVI was absent (at 20 years, 32%; 95% CI 26% to 39%). In the ≥75% sTILs subgroup, the presence of LVI might be associated with poor survival (HR 11.45, 95% CI 0.71-182.36, two deaths). We confirm the lack of prognostic value of androgen receptor expression and human epidermal growth factor receptor 2 -low status. Conclusions: sTILs, LVI and fibrotic focus provide independent prognostic information in young women with node-negat

Published
2024

7. Blended online learning for oncologists to improve skills in shared decision making about palliative chemotherapy: a pre-posttest evaluation

Author

MS Medische Oncologie, Cancer, Bos-van den Hoek, D W, van Laarhoven, H W M, Ali, R, Bakker, S D, Goosens, A, Hendriks, M P, Pepels, M J A E, Tange, D, de Vos, F Y F L, van de Wouw, A J, Smets, E M A, Henselmans, I, MS Medische Oncologie, Cancer, Bos-van den Hoek, D W, van Laarhoven, H W M, Ali, R, Bakker, S D, Goosens, A, Hendriks, M P, Pepels, M J A E, Tange, D, de Vos, F Y F L, van de Wouw, A J, Smets, E M A, and Henselmans, I

Published
2023

8. Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19:an update from the Dutch Oncology COVID-19 Consortium

Author

de Joode, Karlijn, Tol, Jolien, Hamberg, Paul, Cloos, Marissa, Kastelijn, Elisabeth A., Borgers, Jessica S.W., Nuij, Veerle J.A.A., Klaver, Yarne, Herder, Gerarda J.M., Mutsaers, Pim G.N.J., Dumoulin, Daphne W., Oomen-de Hoop, Esther, van Diemen, Nico G.J., Libourel, Eduard J., Geraedts, Erica J., Bootsma, Gerben P., van der Leest, Cor H., Peerdeman, Anne L., Herbschleb, Karin H., Visser, Otto J., Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., de Vries, Elisabeth G.E., Hendriks, Lizza E.L., Beerepoot, Laurens V., Westgeest, Hans M., van den Berkmortel, Franchette W.P.J., Dingemans, Anne Marie C., van der Veldt, Astrid A.M., van Leeuwen, L., van der Meer, F. S., Tiemessen, M. A., van Diepen, D. M., Brocken, P., Drooger, J. C., de Groot, J. W.B., Stigt, J. A., Slingerland, M., Haberkorn, B. C.M., Aarts, M. J.B., Youssef, M., Faber, L. M., van de Wetering, R. A.W., Bard, M. P.L., Douma, G., Suijkerbuijk, K. P.M., Bakker, S. D., de Jong, W. K., Staal, A. J., Franken, B., de Joode, Karlijn, Tol, Jolien, Hamberg, Paul, Cloos, Marissa, Kastelijn, Elisabeth A., Borgers, Jessica S.W., Nuij, Veerle J.A.A., Klaver, Yarne, Herder, Gerarda J.M., Mutsaers, Pim G.N.J., Dumoulin, Daphne W., Oomen-de Hoop, Esther, van Diemen, Nico G.J., Libourel, Eduard J., Geraedts, Erica J., Bootsma, Gerben P., van der Leest, Cor H., Peerdeman, Anne L., Herbschleb, Karin H., Visser, Otto J., Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., de Vries, Elisabeth G.E., Hendriks, Lizza E.L., Beerepoot, Laurens V., Westgeest, Hans M., van den Berkmortel, Franchette W.P.J., Dingemans, Anne Marie C., van der Veldt, Astrid A.M., van Leeuwen, L., van der Meer, F. S., Tiemessen, M. A., van Diepen, D. M., Brocken, P., Drooger, J. C., de Groot, J. W.B., Stigt, J. A., Slingerland, M., Haberkorn, B. C.M., Aarts, M. J.B., Youssef, M., Faber, L. M., van de Wetering, R. A.W., Bard, M. P.L., Douma, G., Suijkerbuijk, K. P.M., Bakker, S. D., de Jong, W. K., Staal, A. J., and Franken, B.

Abstract

Aim of the study: The coronavirus disease 2019 (COVID-19) pandemic significantly impacted cancer care. In this study, clinical patient characteristics related to COVID-19 outcomes and advanced care planning, in terms of non-oncological treatment restrictions (e.g. do-not-resuscitate codes), were studied in patients with cancer and COVID-19. Methods: The Dutch Oncology COVID-19 Consortium registry was launched in March 2020 in 45 hospitals in the Netherlands, primarily to identify risk factors of a severe COVID-19 outcome in patients with cancer. Here, an updated analysis of the registry was performed, and treatment restrictions (e.g. do-not-intubate codes) were studied in relation to COVID-19 outcomes in patients with cancer. Oncological treatment restrictions were not taken into account. Results: Between 27th March 2020 and 4th February 2021, 1360 patients with cancer and COVID-19 were registered. Follow-up data of 830 patients could be validated for this analysis. Overall, 230 of 830 (27.7%) patients died of COVID-19, and 60% of the remaining 600 patients with resolved COVID-19 were admitted to the hospital. Patients with haematological malignancies or lung cancer had a higher risk of a fatal outcome than other solid tumours. No correlation between anticancer therapies and the risk of a fatal COVID-19 outcome was found. In terms of end-of-life communication, 50% of all patients had restrictions regarding life-prolonging treatment (e.g. do-not-intubate codes). Most identified patients with treatment restrictions had risk factors associated with fatal COVID-19 outcome. Conclusion: There was no evidence of a negative impact of anticancer therapies on COVID-19 outcomes. Timely end-of-life communication as part of advanced care planning could save patients from prolonged suffering and decrease burden in intensive care units. Early discussion of treatment restrictions should therefore be part of routine oncological care, especially during the COVID-19 pandemic.

Published
2022

9. Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature

Author

MS CGO, MS Medische Oncologie, Cancer, Pathologie, Opdam, M, van der Noort, V, Kleijn, M, Glas, A, Mandjes, I, Kleiterp, S, Hilbers, F S, Kruger, D T, Bins, A D, de Jong, P C, Schiphorst, P P J B M, van Dalen, T, Flameling, B, Rietbroek, R C, Beeker, A, van den Heiligenberg, S M, Bakker, S D, Wymenga, A N M, Oving, I M, Bijlsma, R M, van Diest, P J, Vermorken, J B, van Tinteren, H, Linn, S C, MS CGO, MS Medische Oncologie, Cancer, Pathologie, Opdam, M, van der Noort, V, Kleijn, M, Glas, A, Mandjes, I, Kleiterp, S, Hilbers, F S, Kruger, D T, Bins, A D, de Jong, P C, Schiphorst, P P J B M, van Dalen, T, Flameling, B, Rietbroek, R C, Beeker, A, van den Heiligenberg, S M, Bakker, S D, Wymenga, A N M, Oving, I M, Bijlsma, R M, van Diest, P J, Vermorken, J B, van Tinteren, H, and Linn, S C

Published
2022

10. Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium

Author

MS Medische Oncologie, Infection & Immunity, Cancer, Longziekten, de Joode, Karlijn, Tol, Jolien, Hamberg, Paul, Cloos, Marissa, Kastelijn, Elisabeth A., Borgers, Jessica S.W., Nuij, Veerle J.A.A., Klaver, Yarne, Herder, Gerarda J.M., Mutsaers, Pim G.N.J., Dumoulin, Daphne W., Oomen-de Hoop, Esther, van Diemen, Nico G.J., Libourel, Eduard J., Geraedts, Erica J., Bootsma, Gerben P., van der Leest, Cor H., Peerdeman, Anne L., Herbschleb, Karin H., Visser, Otto J., Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., de Vries, Elisabeth G.E., Hendriks, Lizza E.L., Beerepoot, Laurens V., Westgeest, Hans M., van den Berkmortel, Franchette W.P.J., Haanen, John B.A.G., Dingemans, Anne Marie C., van der Veldt, Astrid A.M., Becker-Commissaris, A., Terheggen, F., van den Borne, B. E.E.M., van Warmerdam, L. J.C., van Leeuwen, L., van der Meer, F. S., Tiemessen, M. A., van Diepen, D. M., Strobbe, L., Koekkoek, J. A.F., Brocken, P., Drooger, J. C., de Groot, J. W.B., Aarts, M. J.B., Cirkel, G. A., Claessens, N. J.M., Jalving, M., Suijkerbuijk, K. P.M., van Lindert, A. S.R., Bakker, S. D., MS Medische Oncologie, Infection & Immunity, Cancer, Longziekten, de Joode, Karlijn, Tol, Jolien, Hamberg, Paul, Cloos, Marissa, Kastelijn, Elisabeth A., Borgers, Jessica S.W., Nuij, Veerle J.A.A., Klaver, Yarne, Herder, Gerarda J.M., Mutsaers, Pim G.N.J., Dumoulin, Daphne W., Oomen-de Hoop, Esther, van Diemen, Nico G.J., Libourel, Eduard J., Geraedts, Erica J., Bootsma, Gerben P., van der Leest, Cor H., Peerdeman, Anne L., Herbschleb, Karin H., Visser, Otto J., Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., de Vries, Elisabeth G.E., Hendriks, Lizza E.L., Beerepoot, Laurens V., Westgeest, Hans M., van den Berkmortel, Franchette W.P.J., Haanen, John B.A.G., Dingemans, Anne Marie C., van der Veldt, Astrid A.M., Becker-Commissaris, A., Terheggen, F., van den Borne, B. E.E.M., van Warmerdam, L. J.C., van Leeuwen, L., van der Meer, F. S., Tiemessen, M. A., van Diepen, D. M., Strobbe, L., Koekkoek, J. A.F., Brocken, P., Drooger, J. C., de Groot, J. W.B., Aarts, M. J.B., Cirkel, G. A., Claessens, N. J.M., Jalving, M., Suijkerbuijk, K. P.M., van Lindert, A. S.R., and Bakker, S. D.

Published
2022

11. Feasibility and outcomes of a goal-directed physical therapy program for patients with metastatic breast cancer

Author

Groen, W. G., primary, ten Tusscher, M. R., additional, Verbeek, R., additional, Geleijn, E., additional, Sonke, G. S., additional, Konings, I. R., additional, Van der Vorst, M. J., additional, van Zweeden, A. A., additional, Schrama, J. G., additional, Vrijaldenhoven, S., additional, Bakker, S. D., additional, Aaronson, N. K., additional, and Stuiver, M. M., additional

Published
2020
Full Text
View/download PDF

12. Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study

Author

MS Medische Oncologie, Cancer, Infection & Immunity, Longziekten, de Joode, Karlijn, Dumoulin, Daphne W., Tol, Jolien, Westgeest, Hans M., Beerepoot, Laurens V., van den Berkmortel, Franchette W.P.J., Mutsaers, Pim G.N.J., van Diemen, Nico G.J., Visser, Otto J., Oomen-de Hoop, Esther, Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., Hendriks, Lizza E.L., Haanen, John B.A.G., de Vries, Elisabeth G.E., Dingemans, Anne Marie C., van der Veldt, Astrid A.M., van Loenhout, C. J., van der Leest, C. H., Becker-Commissaris, A., Borgers, J. S.W., Terhegggen, F., van den Borne, B. E.E.M., van Warmerdam, L. J.C., van Leeuwen, L., van der Meer, F. S., Tiemessen, M. A., van Diepen, D. M., Klaver, Y., Hamberg, A. P., Libourel, E. J., Strobbe, L., Cloos, M., Geraedts, E. J., Drooger, J. C., Heller, R., de Groot, J. W.B., Stigt, J. A., Nuij, V. J.A.A., Pitz, C. C.M., Slingerland, M., Borm, F. J., Haberkorn, B. C.M., Westeinde, S. C.van t., Aarts, M. J.B., van Putten, J. W.G., Youssef, M., Cirkel, G. A., Herder, G. J.M., van Rooijen, C. R., Citgez, E., Barlo, N. P., Scholtes, B. M.J., Koornstra, R. H.T., Claessens, N. J.M., Faber, L. M., Rikers, C. H., van de Wetering, R. A.W., Veurink, G. L., Bouter, B. W., Houtenbos, I., Bard, M. P.L., Herbschleb, K. H., Kastelijn, E. A., Brocken, P., Douma, G., Jalving, M., Hiltermann, T. J.N., Schuurbiers-Siebers, O. C.J., Suijkerbuijk, K. P.M., van Lindert, A. S.R., van de Wouw, A. J., van den Boogaart, V. E.M., Bakker, S. D., Looysen, E., Peerdeman, A. L., de Jong, W. K., Siemerink, E. J.M., Staal, A. J., Franken, B., van Geffen, W. H., Bootsma, G. P., MS Medische Oncologie, Cancer, Infection & Immunity, Longziekten, de Joode, Karlijn, Dumoulin, Daphne W., Tol, Jolien, Westgeest, Hans M., Beerepoot, Laurens V., van den Berkmortel, Franchette W.P.J., Mutsaers, Pim G.N.J., van Diemen, Nico G.J., Visser, Otto J., Oomen-de Hoop, Esther, Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., Hendriks, Lizza E.L., Haanen, John B.A.G., de Vries, Elisabeth G.E., Dingemans, Anne Marie C., van der Veldt, Astrid A.M., van Loenhout, C. J., van der Leest, C. H., Becker-Commissaris, A., Borgers, J. S.W., Terhegggen, F., van den Borne, B. E.E.M., van Warmerdam, L. J.C., van Leeuwen, L., van der Meer, F. S., Tiemessen, M. A., van Diepen, D. M., Klaver, Y., Hamberg, A. P., Libourel, E. J., Strobbe, L., Cloos, M., Geraedts, E. J., Drooger, J. C., Heller, R., de Groot, J. W.B., Stigt, J. A., Nuij, V. J.A.A., Pitz, C. C.M., Slingerland, M., Borm, F. J., Haberkorn, B. C.M., Westeinde, S. C.van t., Aarts, M. J.B., van Putten, J. W.G., Youssef, M., Cirkel, G. A., Herder, G. J.M., van Rooijen, C. R., Citgez, E., Barlo, N. P., Scholtes, B. M.J., Koornstra, R. H.T., Claessens, N. J.M., Faber, L. M., Rikers, C. H., van de Wetering, R. A.W., Veurink, G. L., Bouter, B. W., Houtenbos, I., Bard, M. P.L., Herbschleb, K. H., Kastelijn, E. A., Brocken, P., Douma, G., Jalving, M., Hiltermann, T. J.N., Schuurbiers-Siebers, O. C.J., Suijkerbuijk, K. P.M., van Lindert, A. S.R., van de Wouw, A. J., van den Boogaart, V. E.M., Bakker, S. D., Looysen, E., Peerdeman, A. L., de Jong, W. K., Siemerink, E. J.M., Staal, A. J., Franken, B., van Geffen, W. H., and Bootsma, G. P.

Published
2020

13. Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer.

Author

de Boo LW, Jóźwiak K, Ter Hoeve ND, van Diest PJ, Opdam M, Wang Y, Schmidt MK, de Jong V, Kleiterp S, Cornelissen S, Baars D, Koornstra RHT, Kerver ED, van Dalen T, Bins AD, Beeker A, van den Heiligenberg SM, de Jong PC, Bakker SD, Rietbroek RC, Konings IR, Blankenburgh R, Bijlsma RM, Imholz ALT, Stathonikos N, Vreuls W, Sanders J, Rosenberg EH, Koop EA, Varga Z, van Deurzen CHM, Mooyaart AL, Córdoba A, Groen E, Bart J, Willems SM, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Broeks A, Voogd AC, van der Wall E, Siesling S, Salgado R, Dackus GMHE, Hauptmann M, Kok M, and Linn SC

Subjects
Humans, Female, Prognosis, Lymphocytes, Tumor-Infiltrating metabolism, Lymphocytes, Tumor-Infiltrating pathology, Biomarkers, Tumor, Chemotherapy, Adjuvant, Triple Negative Breast Neoplasms drug therapy, Triple Negative Breast Neoplasms pathology
Abstract

Background: In the absence of prognostic biomarkers, most patients with early-stage triple-negative breast cancer (eTNBC) are treated with combination chemotherapy. The identification of biomarkers to select patients for whom treatment de-escalation or escalation could be considered remains an unmet need. We evaluated the prognostic value of histopathologic traits in a unique cohort of young, (neo)adjuvant chemotherapy-naïve patients with early-stage (stage I or II), node-negative TNBC and long-term follow-up, in relation to stromal tumor-infiltrating lymphocytes (sTILs) for which the prognostic value was recently reported., Materials and Methods: We studied all 485 patients with node-negative eTNBC from the population-based PARADIGM cohort which selected women aged <40 years diagnosed between 1989 and 2000. None of the patients had received (neo)adjuvant chemotherapy according to standard practice at the time. Associations between histopathologic traits and breast cancer-specific survival (BCSS) were analyzed with Cox proportional hazard models., Results: With a median follow-up of 20.0 years, an independent prognostic value for BCSS was observed for lymphovascular invasion (LVI) [adjusted (adj.) hazard ratio (HR) 2.35, 95% confidence interval (CI) 1.49-3.69], fibrotic focus (adj. HR 1.61, 95% CI 1.09-2.37) and sTILs (per 10% increment adj. HR 0.75, 95% CI 0.69-0.82). In the sTILs <30% subgroup, the presence of LVI resulted in a higher cumulative incidence of breast cancer death (at 20 years, 58%; 95% CI 41% to 72%) compared with when LVI was absent (at 20 years, 32%; 95% CI 26% to 39%). In the ≥75% sTILs subgroup, the presence of LVI might be associated with poor survival (HR 11.45, 95% CI 0.71-182.36, two deaths). We confirm the lack of prognostic value of androgen receptor expression and human epidermal growth factor receptor 2 -low status., Conclusions: sTILs, LVI and fibrotic focus provide independent prognostic information in young women with node-negative eTNBC. Our results are of importance for the selection of patients for de-escalation and escalation trials., Competing Interests: Disclosure PJvD has advisory relationships with Paige, Pantarei and Samantree, paid to the institution, and research grants paid to the institute from Pfizer. NS received institutional research funding from Pfizer. ZV has a consulting role for Roche. CHMvD received institutional research funding from AstraZeneca/Daiichi Sankyo. SMW has a consulting role for Roche, and received institutional research funding from Roche, Pfizer, Bayer, MSD, AstraZeneca/Merck and Amgen. SMW has a consulting role for IDDI, Sensorion, Biophytis, Servier, Yuhan, Amaris Consulting and Roche. JW received institutional research funding from Cancer Research UK and KWF Dutch Cancer Society. AR has a consulting role for MSD Oncology, Amgen, Roche, AstraZeneca/Daiichi Sankyo and Bristol Myers Squibb/Pfizer. SCL reports grants from ZonMw and A Sister’s Hope during the conduct of the study; has been an advisory board member for AstraZeneca, Cergentis, IBM, Novartis, Pfizer, Sanofi and Roche; and received institutional research grants from Agendia, AstraZeneca, Eurocept-pharmaceuticals and Merck and Pfizer. In addition, SCL received institutional research grants and institutional non-financial support from Agendia, Genentech, Novartis, Roche, Tesaro and Immunomedics and other institutional support from AstraZeneca, Pfizer, Cergentis, Daiichi Sankyo, IBM and Bayer outside the submitted work. MK is an advisory board member and/or received speakers’ fee for/from Alderaan, Bristol Myers Squibb (BMS), Domain Therapeutics, Gilead, Roche, Medscape, MSD and AZ/Daiichi and received institutional research support from AstraZeneca/Daiichi, BMS and Roche outside the submitted work. RS reports non-financial support from Merck and BMS, research support from Merck, Puma Biotechnology and Roche, and personal fees from Roche, BMS and Exact Sciences for advisory boards. IRK received research grants from Novartis and Gilead. RHTK is an advisory board member for Amgen, AstraZeneca, Bayer, BMS, MSD, Novartis, Pfizer, Pierre Fabre Sante, Sanofi and Servier. All other authors have declared no conflicts of interest., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)

Published
2024
Full Text
View/download PDF

14. [Vertigo as the first manifestation of ovarian cancer].

Author

Weiland MTD, van Oosterhout WPJ, and Bakker SD

Subjects
Aged, Diagnosis, Differential, Female, Humans, Ovarian Neoplasms complications, Paraneoplastic Cerebellar Degeneration complications, Positron Emission Tomography Computed Tomography, Vertigo etiology, Ovarian Neoplasms diagnosis, Paraneoplastic Cerebellar Degeneration diagnosis, Vertigo diagnosis
Abstract

Background: Vertigo is a common complaint and may rarely be the presenting symptom of a paraneoplastic neurological syndrome (PNS)., Case Description: A 76-year-old woman presented at the ER with subacute cerebellar syndrome and severe vertigo. Laboratory testing revealed mild anaemia. A cerebral CT scan showed no intracranial pathology. The patient was admitted for observation. History-taking revealed she been suffering from general malaise and had unintentionally lost 16 kg in weight over recent months. Further PET-CT investigations revealed multiple enlarged mediastinal and abdominal lymph nodes with high metabolic activity. Histopathological investigation of a lymph node biopsy showed a malignancy originating from the genital tract. Positive anti-neuronal antibodies (anti-Yo) and an elevated CA-125 concentration were found in peripheral blood. We diagnosed paraneoplastic cerebellar degeneration as the first manifestation of hitherto undiagnosed occult ovarian cancer., Conclusion: In a patient with subacute, cerebellar syndrome with severe vertigo, after ruling out other causes, the diagnosis of PNS should be considered. Determination of anti-neuronal antibodies can help in the diagnosis. Early recognition of PNS is important for the diagnosis and treatment of the underlying malignancy.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results